Macdougall Mary, Steiner Meir
Women's Health Concerns Clinic, St Joseph's Healthcare, Fontbonne Building, 301 James Street S., Hamilton, Ontario L8P 3B6, Canada.
Expert Opin Drug Saf. 2003 Mar;2(2):161-6. doi: 10.1517/14740338.2.2.161.
Many women experience physical or mood symptoms associated with the menstrual cycle. For approximately 3 - 8% of women, the symptoms are severe enough to significantly affect social, domestic and occupational functioning. This cluster of primarily emotional and behavioural symptoms is now labelled premenstrual dysphoric disorder (PMDD). Women who meet criteria for PMDD do not usually respond to conservative interventions; selective serotonin re-uptake inhibitors (SSRIs) taken either daily or intermittently are considered to be an effective first-line therapy for this population. In this paper, the authors report on the efficacy and tolerability of SSRIs that are currently recognised as the treatment of choice for PMDD.
许多女性会经历与月经周期相关的身体或情绪症状。约3%-8%的女性症状严重到足以显著影响社交、家庭和职业功能。这种主要由情绪和行为症状组成的症候群现在被称为经前烦躁障碍（PMDD）。符合PMDD标准的女性通常对保守干预措施没有反应；每日或间歇性服用的选择性5-羟色胺再摄取抑制剂（SSRI）被认为是针对这一人群的有效一线治疗方法。在本文中，作者报告了目前被公认为PMDD治疗选择的SSRI的疗效和耐受性。
